ArticleCJC open2026
Residual Mitral Regurgitation After Transcatheter Edge-to-Edge Repair Worsens Survival in Patients with Renal Dysfunction.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) and postprocedural acute kidney injury (AKI) are predictors of survival after mitral transcatheter edge-to-edge repair (TEER). This study aimed to assess the impact of residual mitral regurgitation (MR) on 3-year mortality in patients with vs without CKD or AKI. Methods: Patients from the prospective, multicentre MITRAClip PROgnosis (MITRA-PRO) registry (n = 1491) were stratified by baseline estimated glomerular filtration rate (eGFR), into 3 groups: > 50, 30-50, and < 30 mL/min per 1.73 m Results: Patients with eGFR < 30 had significantly higher 3-year mortality (55.4%) compared to those with eGFR 30-50 (40.8%) and eGFR > 50 (27.7%, Conclusions: Residual MR following TEER is a strong predictor of long-term mortality, particularly in patients with CKD. Minimizing residual MR may reduce postprocedural AKI and improve survival outcomes in patients with CKD. Clinical Trial Registration: DRKS00012288.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.